MX2020005792A - Anticuerpo anti-pd-l1/anti-cd47 biespecifico con estructura tipo anticuerpo natural y en forma de heterodimero y preparacion del mismo. - Google Patents

Anticuerpo anti-pd-l1/anti-cd47 biespecifico con estructura tipo anticuerpo natural y en forma de heterodimero y preparacion del mismo.

Info

Publication number
MX2020005792A
MX2020005792A MX2020005792A MX2020005792A MX2020005792A MX 2020005792 A MX2020005792 A MX 2020005792A MX 2020005792 A MX2020005792 A MX 2020005792A MX 2020005792 A MX2020005792 A MX 2020005792A MX 2020005792 A MX2020005792 A MX 2020005792A
Authority
MX
Mexico
Prior art keywords
preparation
bispecific antibody
antibody
heterodimer
chain
Prior art date
Application number
MX2020005792A
Other languages
English (en)
Inventor
Maengsup Kim
Jiawang Liu
Nanmeng Song
Yaping Yang
Original Assignee
Beijing Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Hanmi Pharmaceutical Co Ltd filed Critical Beijing Hanmi Pharmaceutical Co Ltd
Publication of MX2020005792A publication Critical patent/MX2020005792A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Abstract

Se proporciona un anticuerpo biespecifico anti-PD-PD-L1/anti-CD47 que tiene características de IgG naturales y está en la forma de un heterodimero altamente estable sin la discordancia de cadena pesada y cadena ligera, y un metodo de preparacion para el mismo; ya sea la primera cadena Fc o la segunda cadena Fc del anticuerpo biespecifico comprende sustituciones de aminoácidos en las posiciones 366 y 399, y la otra comprende las sustituciones de aminoácidos en las posiciones 351, 407 y 409.
MX2020005792A 2017-12-04 2018-12-01 Anticuerpo anti-pd-l1/anti-cd47 biespecifico con estructura tipo anticuerpo natural y en forma de heterodimero y preparacion del mismo. MX2020005792A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711261880 2017-12-04
PCT/CN2018/118800 WO2019109876A1 (zh) 2017-12-04 2018-12-01 抗pd‐l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备

Publications (1)

Publication Number Publication Date
MX2020005792A true MX2020005792A (es) 2020-11-06

Family

ID=66750763

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005792A MX2020005792A (es) 2017-12-04 2018-12-01 Anticuerpo anti-pd-l1/anti-cd47 biespecifico con estructura tipo anticuerpo natural y en forma de heterodimero y preparacion del mismo.

Country Status (14)

Country Link
US (1) US11739151B2 (es)
EP (1) EP3722322A4 (es)
JP (1) JP7231641B2 (es)
KR (1) KR20200093639A (es)
CN (1) CN111615521A (es)
AU (1) AU2018378529A1 (es)
BR (1) BR112020011295A2 (es)
CA (1) CA3084626A1 (es)
EA (1) EA202091364A1 (es)
IL (1) IL275135A (es)
MX (1) MX2020005792A (es)
SG (1) SG11202005216XA (es)
WO (1) WO2019109876A1 (es)
ZA (1) ZA202003382B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019006074A2 (pt) * 2016-09-29 2019-06-18 Beijing Hanmi Pharmaceutical Co Ltd heterodímero, método de produção do heterodímero, métodos de produção de um heterodímero, ácido nucleico, vetor ou sistema de vetores, célula, composição farmacêutica e método de tratamento ou prevenção de uma doença ou distúrbio em um sujeito em necessidade do mesmo
EP3533804A4 (en) 2016-11-18 2020-06-17 Beijing Hanmi Pharmaceutical Co., Ltd. BISPECIFIC ANTIBODY TYPE ANTI-PD -1 / ANTI-HER2 NATURAL ANTIBODY HETERODIMERIC FORM AND PREPARATION THEREOF
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
JP7369297B2 (ja) * 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
EP4112647A4 (en) * 2020-02-28 2024-03-27 Nanjing Sanhome Pharmaceutical Co Ltd ANTI-CD47/ANTI-PD-L1 ANTIBODIES AND ITS USES
WO2022072718A1 (en) 2020-09-30 2022-04-07 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
KR20230083300A (ko) * 2020-10-07 2023-06-09 셀진 코포레이션 림프계 악성 신생물 병태의 이중특이성 항체 치료
US20230406921A1 (en) * 2020-11-12 2023-12-21 Mabwell (shanghai) Bioscience Co., Ltd. Antibody and preparation method therefor
EP4276115A1 (en) * 2021-01-08 2023-11-15 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-1/anti-cd47 natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
JP2024503396A (ja) * 2021-01-08 2024-01-25 北京韓美薬品有限公司 Ｃｄ４７と特異的に結合する抗体及びその抗原結合フラグメント
EP4313309A1 (en) * 2021-03-22 2024-02-07 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
TW202305006A (zh) * 2021-05-07 2023-02-01 南韓商益免安協公司 與ｃｄ４７及ｐｄ—ｌ１特異性結合的雙特異性抗體
CN115702931A (zh) * 2021-08-06 2023-02-17 百奥泰生物制药股份有限公司 抗pd-l1/cd47双特异抗体在治疗疾病中的应用
WO2023140950A1 (en) * 2022-01-18 2023-07-27 Fbd Biologics Limited Cd47/pd-l1-targeting protein complex and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031994A2 (en) * 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
SG196798A1 (en) * 2008-12-09 2014-02-13 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
PL2635607T3 (pl) * 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
SG10201913376XA (en) * 2012-04-20 2020-02-27 Merus Nv Methods and means for the production of ig-like molecules
CA3155275A1 (en) 2012-12-03 2014-06-12 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
PL3180363T3 (pl) * 2014-08-15 2020-02-28 Merck Patent Gmbh Białka fuzyjne immunoglobulin sirp-alfa
JP6850255B2 (ja) * 2014-12-30 2021-03-31 セルジーン コーポレイション 抗−ｃｄ４７抗体及びその使用
PT3331902T (pt) 2015-08-07 2021-07-26 Alx Oncology Inc Construções com um domínio de sirp-alfa ou uma sua variante
MX2018003374A (es) * 2015-09-18 2018-11-09 Arch Oncology Inc Anticuerpos terapeuticos cd47.
CN106883297B (zh) * 2015-12-16 2019-12-13 苏州康宁杰瑞生物科技有限公司 基于ch3结构域的异二聚体分子、其制备方法及用途
WO2017167350A1 (en) * 2016-03-30 2017-10-05 Horst Lindhofer Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
BR112019006074A2 (pt) * 2016-09-29 2019-06-18 Beijing Hanmi Pharmaceutical Co Ltd heterodímero, método de produção do heterodímero, métodos de produção de um heterodímero, ácido nucleico, vetor ou sistema de vetores, célula, composição farmacêutica e método de tratamento ou prevenção de uma doença ou distúrbio em um sujeito em necessidade do mesmo
EP3533804A4 (en) * 2016-11-18 2020-06-17 Beijing Hanmi Pharmaceutical Co., Ltd. BISPECIFIC ANTIBODY TYPE ANTI-PD -1 / ANTI-HER2 NATURAL ANTIBODY HETERODIMERIC FORM AND PREPARATION THEREOF
WO2019047885A1 (en) * 2017-09-07 2019-03-14 Dingfu Biotarget Co., Ltd. IMMUNOCONJUGATES COMPRISING ALPHA REGULATORY SIGNAL PROTEIN
EA039662B1 (ru) * 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
BR112020010020A2 (pt) * 2017-11-20 2020-11-10 Taizhou Mabtech Pharmaceutical Co., Ltd uma proteína de fusão bifuncional direcionada a cd47 e pd-l1
EP4112647A4 (en) * 2020-02-28 2024-03-27 Nanjing Sanhome Pharmaceutical Co Ltd ANTI-CD47/ANTI-PD-L1 ANTIBODIES AND ITS USES

Also Published As

Publication number Publication date
CN111615521A (zh) 2020-09-01
US11739151B2 (en) 2023-08-29
ZA202003382B (en) 2021-06-30
IL275135A (en) 2020-07-30
SG11202005216XA (en) 2020-07-29
AU2018378529A1 (en) 2020-06-18
KR20200093639A (ko) 2020-08-05
EP3722322A4 (en) 2021-09-15
EP3722322A1 (en) 2020-10-14
EA202091364A1 (ru) 2020-10-13
JP7231641B2 (ja) 2023-03-01
CA3084626A1 (en) 2019-06-13
JP2021505195A (ja) 2021-02-18
BR112020011295A2 (pt) 2020-11-24
WO2019109876A1 (zh) 2019-06-13
US20210230277A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MX2020005792A (es) Anticuerpo anti-pd-l1/anti-cd47 biespecifico con estructura tipo anticuerpo natural y en forma de heterodimero y preparacion del mismo.
CY1120849T1 (el) Αντισωμα που συνδεεται σε ανθρωπινο cd3
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
MX2019014265A (es) Tratamientos conjuntos triples con anticuerpos.
EP3621642A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST LAG3 AND THEIR USES
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
MX2019000730A (es) Proteinas multiespecificas de union al antigeno y metodos de uso de estas.
EP3535586A4 (en) ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGUE LOBULIN AND MUCIN PROTEIN 3 (TIM-3)
EP3746486A4 (en) Anti-ctla4 antibodies and methods of making and using the same
AR111418A1 (es) Dominios de unión a antígeno humanizados y métodos de uso
EP3589660A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
WO2016073906A3 (en) Transforming growth factor-related immunoassays
BR112018015480A2 (pt) proteínas de ligação ao antígeno que se ligam a pd-l1
NZ732628A (en) Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof
EP3575322A4 (en) ANTI-PD-1 MONOCLONAL ANTIBODY, PROCESS OF PREPARATION AND APPLICATION
EP4039707A4 (en) CD3-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND USE THEREOF
EP3750920A4 (en) BISPECIFIC ANTIBODY IN HETERODIMER FORM SIMILAR TO A NATURAL ANTI-PD-1 / ANTI-VEGF ANTIBODY STRUCTURE AND PRODUCTION OF IT
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
MX2018012651A (es) Composiciones que comprenden coformulacion de anticuerpos anti-ligando-1 de muerte celular programada (pd-l1) y anti-antigeno-4 asociado a linfocitos t citotoxicos (ctla-4).
EP3824096A4 (en) NOVEL ANTIBODIES AND METHODS FOR THE PREPARATION AND USE THEREOF
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
MX2019011748A (es) Anticuerpo biespecífico heterodimérico tipo estructura de anticuerpo natural anti-pd-l1/anti-pd-1 y preparación del mismo.
EP3778635A4 (en) ANTI-PD-L1 ANTIBODIES AND ITS USE
EP3568417A4 (en) ANTI-PD-L1 ANTIBODIES AND IL-7 FUSIONS
AU2017255888A1 (en) Humanized anti-BASIGIN antibodies and the use thereof